Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBupropion hydrochloride
Description: Non-selective inhibitor of dopamine and noradrenalin transporters
Chemical Name: 1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for Bupropion hydrochloride
Bupropion hydrochloride is a non-selective inhibitor of dopamine and noradrenalin transporters (Ki values are 1.4, 2.8 and 45 μM for NET, DAT and SERT transporters respectively). Also inhibits neuronal nicotinic acetylcholine receptors. Displays antidepressant activity and augments nicotine self-administration at low doses in vivo.
Compound Libraries for Bupropion hydrochloride
Bupropion hydrochloride is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
Technical Data for Bupropion hydrochloride
| M. Wt | 276.2 |
| Formula | C13H18ClNO.HCl |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 31677-93-7 |
| PubChem ID | 62884 |
| InChI Key | HEYVINCGKDONRU-UHFFFAOYSA-N |
| Smiles | ClC1=CC=CC(C(C(C)NC(C)(C)C)=O)=C1.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Bupropion hydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 27.62 | 100 | |
| DMSO | 27.62 | 100 |
Preparing Stock Solutions for Bupropion hydrochloride
The following data is based on the product molecular weight 276.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.62 mL | 18.1 mL | 36.21 mL |
| 5 mM | 0.72 mL | 3.62 mL | 7.24 mL |
| 10 mM | 0.36 mL | 1.81 mL | 3.62 mL |
| 50 mM | 0.07 mL | 0.36 mL | 0.72 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Bupropion hydrochloride
References for Bupropion hydrochloride
References are publications that support the biological activity of the product.
Slemmer et al (2000) Bupropion is a nicotinic antagonist. J.Pharmacol.Exp.Ther. 295 321 PMID: 10991997
Torres et al (2003) Plasma membrane monoamine transporters: structure regulation and function. Nat.Rev.Neurosci. 4 13 PMID: 12511858
Dwoskin et al (2006) Review of the pharmacology and clinical profile of bupropion, antidepressant and tobacco use cessation agent. CNS Drug Rev. 12 178 PMID: 17227286
If you know of a relevant reference for Bupropion hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bupropion hydrochloride, Bupropion hydrochloride supplier, Non-Selective, inhibitors, inhibits, dopamine, noradrenaline, transporters, NET, Adrenergic, Monoamine, Neurotransmitter, DAT, Dopamine, reuptake, Transporters, 2831, Tocris Bioscience
4 Citations for Bupropion hydrochloride
Citations are publications that use Tocris products. Selected citations for Bupropion hydrochloride include:
Durham et al (2019) Direct Effects of Nicotine Exposure on Murine Calvaria and Calvarial Cells. Sci Rep 9 3805 PMID: 30846819
Li et al (2009) Activation of glycogen synthase kinase-3 β is required for hyperDA and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. Neuropsychopharmacology 29 15551 PMID: 20007479
Nunes et al (2013) Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33 19120 PMID: 24305809
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Cardiovasc Res 40 766 PMID: 25249058
Do you know of a great paper that uses Bupropion hydrochloride from Tocris? Please let us know.
Reviews for Bupropion hydrochloride
There are currently no reviews for this product. Be the first to review Bupropion hydrochloride and earn rewards!
Have you used Bupropion hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.